Altogether, simultaneous targeting of type I interferon towards Clec9A and PD-L1 in a Bisp-AFN construct induces strong tumor-specific immune responses and increases diversity in the CD8+ T cell TCR repertoire without the need for tumor markers, as such representing a potent immunotherapeutic with broad applications. This evidence concerns the gene CLEC9A and neoplasm.